|Bupropion||Norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist|
Bupropion/zonisamide (planned trade name Empatic) is an experimental drug combination for the treatment of obesity. It is being developed by Orexigen Therapeutics. It is currently at phase II testing. The combination consists of two prescription medications approved by the U.S. Food and Drug Administration (FDA) for other ailments. When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo.
Empatic was called Excalia before its name was changed.
- Empatic Shows Long-Term Weight Loss, Improved Quality Of Life Contrave(R) Reduces Rate Of Metabolic Syndrome By Half
- Ioannides-Demos, LL; Piccenna, L; McNeil, JJ (2011). "Pharmacotherapies for obesity: past, current, and future therapies" (PDF). Journal of Obesity. 2011: 179674. doi:10.1155/2011/179674. PMC 3006492. PMID 21197148.
- Adan, RAH (February 2013). "Mechanisms underlying current and future anti-obesity drugs". Trends in Neurosciences. 36 (2): 133–140. doi:10.1016/j.tins.2012.12.001. PMID 23312373.
- Orexigen says trial of 2nd obesity drug meets goal
- Empatic Obesity Drug Information and News
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|